Polypharmacy was present in 10.3% of Iranian patients with metabolic syndrome, with significantly higher odds in urban areas (OR 2.326; 95% CI 1.645-3.288; p<0.001).
Cross-Sectional (n=2,075)
Yes
In Iranian patients with metabolic syndrome, polypharmacy and potentially inappropriate medication use are significantly associated with older age and urban residency, highlighting the need for preventive measures in these populations.
ABSTRACT Background and Aims Polypharmacy, characterized by the concurrent use of five or more medications in a prescription, potentially resulting in adverse outcomes, is frequently observed among individuals with metabolic syndrome, which encompasses a collection of conditions that co‐occur, heightening the likelihood of heart disease, stroke, and type 2 diabetes. This study seeks to ascertain the prevalence of polypharmacy and the use of potentially inappropriate medications (PIMs) among Iranian patients with metabolic syndrome, while also evaluating the contributing individual and sociodemographic factors. Methods This was a population‐based, cross‐sectional national study. Two databases were used: (a) Iranians Health Insurance Service database and (b) Iran's STEPS 2016 survey. Patients with metabolic syndrome conjoint in both databases were selected. Among these patients, polypharmacy and PIM were evaluated, and their association with individual and sociodemographic factors was assessed. Univariate and multivariate logistic regression were used to analyze the associations. All statistical analyses were done using SPSS 22 and Python 3. Results Out of 2075 metabolic syndrome patients, 10.3% had polypharmacy. Polypharmacy significantly increased by age (OR: 4.334, adjusted for > 80‐year‐olds vs. 25–39‐year‐olds CI: 1.664–11.283, p < 0.001), and its prevalence was significantly higher in urban areas (OR: 2.326 CI: 1.645–3.288, p < 0.001). Polypharmacy was 5.88% in West, 5.41% in Southeast, 5.04% in Central, and 4.83% in North‐Northeast of Iran. PIM was 13.2% in ≥ 60 years and significantly higher in urban areas (OR: 2.014 CI: 1.153–3.519, p < 0.001). Conclusions Since the area of residency affects polypharmacy and PIM more significantly than wealth status and education level, it is important to implement preventive measures in urban areas.
Daneshmand et al. (Tue,) conducted a cross-sectional in Metabolic syndrome (n=2,075). Polypharmacy and Potentially Inappropriate Medication was evaluated on Prevalence of polypharmacy. Polypharmacy was present in 10.3% of Iranian patients with metabolic syndrome, with significantly higher odds in urban areas (OR 2.326; 95% CI 1.645-3.288; p<0.001).